Company profile: Bellus Health
1.1 - Company Overview
Company description
- Provider of drug development for rare diseases, starting with kidney-affecting conditions. Lead program KIACTA, a novel drug candidate, is in data review following top-line results from a Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bellus Health
Autolus Therapeutics
HQ: United Kingdom
Website
- Description: Provider of next-generation programmed T cell therapies for cancer, leveraging T-cell programming and manufacturing technology. Pipeline includes CAR T products such as obe-cel (obecabtagene autoleucel) for adult ALL; AUTO1/22 for pediatric ALL; AUTO4 (TRBC1) and AUTO5 (TRBC2) for peripheral T-cell lymphoma; AUTO6NG (GD2) for neuroblastoma and other solid tumors; and AUTO8 (BCMA/CD19) for multiple myeloma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Autolus Therapeutics company profile →
BlossomHill Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on oncology and autoimmune disorders, including FDA-approved repotrectinib (AUGTYRO) for ROS1+ NSCLC, crizotinib (XALKORI) and lorlatinib (LORBRENA), and pipeline candidates elzovantinib (TPX-0022) and TPX-0046, both in Phase 1 studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlossomHill Therapeutics company profile →
Affiris
HQ: Austria
Website
- Description: Provider of tailor-made peptide vaccines and specific active immunotherapies for chronic diseases, including Alzheimer’s, Parkinson’s, atherosclerosis/hypercholesterolemia and hypertension. Portfolio includes AFFITOPE PD01/PD03 targeting alpha-synuclein, AFFITOPE AT04/AT06 targeting PCSK9 to lower LDL, mAB C6-17 for mutant huntingtin, and the SAIT modality.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affiris company profile →
Cidara Therapeutics
HQ: United States
Website
- Description: Provider of drug-Fc conjugate therapeutics built on the Cloudbreak platform, which couples targeted small molecules and peptides to a human antibody fragment (Fc) to inhibit disease targets and engage the immune system; includes CD388, a Phase 2 DFC for preventing seasonal influenza A and B, and CBO421, an IND-enabling oncology DFC targeting CD73 to enhance anti-tumor immunity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cidara Therapeutics company profile →
Apeiron Biologics
HQ: Austria
Website
- Description: Provider of discovery and development of novel cancer immunotherapies, with products including Qarziba (cancer immunotherapy, licensed to EUSAPharma), APN401 (first-in-class autologous cell therapy inhibiting the immune checkpoint Cbl-b using RNAi to treat solid tumors), and APN01 (inhaled treatment in clinical trials targeting SARS-CoV-2 in the respiratory tract).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apeiron Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bellus Health
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bellus Health
2.2 - Growth funds investing in similar companies to Bellus Health
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bellus Health
4.2 - Public trading comparable groups for Bellus Health
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →